Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OPT’s FA Score shows that 0 FA rating(s) are green whileVTYX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OPT’s TA Score shows that 5 TA indicator(s) are bullish while VTYX’s TA Score has 4 bullish TA indicator(s).
OPT (@Biotechnology) experienced а +8.82% price change this week, while VTYX (@Biotechnology) price change was -5.63% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +4.69%, and the average quarterly price growth was +62.76%.
OPT is expected to report earnings on May 29, 2024.
VTYX is expected to report earnings on Aug 12, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
OPT | VTYX | OPT / VTYX | |
Capitalization | 294M | 294M | 100% |
EBITDA | N/A | N/A | - |
Gain YTD | 21.356 | 69.636 | 31% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
OPT | ||
---|---|---|
OUTLOOK RATING 1..100 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OPT | VTYX | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago79% |
Stochastic ODDS (%) | 2 days ago70% | 2 days ago90% |
Momentum ODDS (%) | 2 days ago72% | 2 days ago87% |
MACD ODDS (%) | 2 days ago86% | 2 days ago90% |
TrendWeek ODDS (%) | 2 days ago60% | 2 days ago85% |
TrendMonth ODDS (%) | 2 days ago60% | 2 days ago84% |
Advances ODDS (%) | 14 days ago77% | 2 days ago85% |
Declines ODDS (%) | 2 days ago84% | 9 days ago84% |
BollingerBands ODDS (%) | 2 days ago81% | N/A |
Aroon ODDS (%) | 2 days ago82% | 2 days ago84% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CCSGX | 24.37 | 0.24 | +0.99% |
Conestoga SMid Cap Institutional | |||
BPTUX | 147.83 | 0.09 | +0.06% |
Baron Partners R6 | |||
LSTIX | 12.96 | N/A | N/A |
Lazard Global Strategic Equity Instl | |||
GSMVX | 16.24 | N/A | N/A |
Goldman Sachs Small/Mid Cap Value Instl | |||
FDFAX | 95.63 | -0.17 | -0.18% |
Fidelity Select Consumer Staples Port |
A.I.dvisor tells us that OPT and QLGN have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OPT and QLGN's prices will move in lockstep.
Ticker / NAME | Correlation To OPT | 1D Price Change % | ||
---|---|---|---|---|
OPT | 100% | -0.83% | ||
QLGN - OPT | 25% Poorly correlated | +7.29% | ||
RANI - OPT | 24% Poorly correlated | -4.33% | ||
VTYX - OPT | 23% Poorly correlated | +0.48% | ||
RLMD - OPT | 22% Poorly correlated | -4.40% | ||
ACST - OPT | 22% Poorly correlated | -3.23% | ||
More |
A.I.dvisor indicates that over the last year, VTYX has been loosely correlated with AURA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VTYX jumps, then AURA could also see price increases.
Ticker / NAME | Correlation To VTYX | 1D Price Change % | ||
---|---|---|---|---|
VTYX | 100% | +0.48% | ||
AURA - VTYX | 58% Loosely correlated | -0.40% | ||
AKRO - VTYX | 52% Loosely correlated | +3.79% | ||
KROS - VTYX | 43% Loosely correlated | +3.03% | ||
CHRS - VTYX | 39% Loosely correlated | +4.81% | ||
ZNTL - VTYX | 38% Loosely correlated | +2.61% | ||
More |